# US 2025/0367190 A1 · Melanocortin subtype-2 receptor (mc2r) antagonist for the treatment of disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367190 A1
- Document ID: US20250367190A1
- Status: Published application
- Kind: A1
- Application number: 19/082,571
- Filed: 2025-03-18
- Published: 2025-12-04
- Earliest claimed: 2021-03-19
- Assignees: Crinetics Pharmaceuticals, Inc.
- Applicants: Crinetics Pharmaceuticals, Inc.
- Inventors: Christine FERRARA-COOK; Alan S. KRASNER
- Web page: https://patentgrep.com/patent/US20250367190A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 5/38: of the suprarenal hormones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods and compositions for the treatment of diseases of ACTH excess, such as Cushing's disease, ectopic ACTH syndrome, and congenital adrenal hyperplasia.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A method of treating congenital adrenal hyperplasia (CAH) in a human, the method comprising administering to the human in need thereof, a compound having the structure of Compound 1, or a pharmaceutically acceptable salt, or solvate thereof:

### Claim 18 (depends on 17)

The method of claim 17, wherein the human has a genetic mutation that result in impaired cortisol synthesis.

### Claim 19 (depends on 17)

The method of claim 17, wherein the human has a mutation in the gene encoding 21β-hydroxylase, 11β-hydroxylase, 17α-hydroxylase, 3β-hydroxysteroid dehydrogenase, and p450 oxidoreductase, or a combination thereof.

### Claim 20 (depends on 17)

The method of claim 17, wherein the CAH is classical CAH.

### Claim 21 (depends on 39)

The method of claim 39, wherein the classical CAH comprises salt-losing CAH or simple-virilizing CAH.

### Claim 22 (depends on 17)

The method of claim 17, wherein the CAH is non-classical CAH.

### Claim 23 (depends on 17)

The method of claim 17, wherein treating CAH comprises reducing levels of ACTH-stimulated androstenedione (A4), 17-hydroxyprogesterone (17-OHP), aldosterone, dehydroepiandrosterone sulfate (DHEAS), dehydroepiandrosterone (DHEA), or a combination thereof, in the human.

### Claim 24 (depends on 17)

The method of claim 17, wherein treating CAH comprises reducing levels of ACTH-stimulated androgens or cortisol precursors in the human.

### Claim 25 (depends on 24)

The method of claim 24, wherein the androgens comprise androstenedione (A4).

### Claim 26 (depends on 24)

The method of claim 24, wherein the cortisol precursors comprise 17-hydroxyprogesterone (17-OHP).

### Claim 27 (depends on 17)

The method of claim 17, wherein treating CAH comprises reducing secretion of androgens.

### Claim 28 (depends on 17)

The method of claim 17, wherein treating CAH comprises reducing incidence of improper gonadal development, hyperandrogenism, and replacement of mineralocorticoids.

### Claim 29 (depends on 17)

The method of claim 17, wherein the administration of Compound 1, or a pharmaceutically acceptable salt, or solvate thereof, comprises reducing exogenous glucocorticoid dose requirements for the human.

### Claim 30 (depends on 17)

The method of claim 17, wherein the administration of Compound I, or a pharmaceutically acceptable salt, or solvate thereof, comprises reducing growth of fat pads (collarbone, back of neck, face and trunk), excessive sweating, dilation of capillaries, thinning of the skin, muscle weakness, hirsutism, depression/anxiety, hypertension, osteoporosis, insulin resistance, hyperglycemia, heart disease, lethargy, obesity, menstrual irregularity, or combinations thereof.

### Claim 31

(canceled)

### Claim 32 (depends on 29)

The method of claim 29, wherein the exogenous glucocorticoid comprises beclomethasone, betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone, or a combination thereof.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 17)

The method of claim 17, wherein Compound 1, or a pharmaceutically acceptable salt, or solvate thereof, is administered orally administered once daily.

### Claim 37 (depends on 17)

The method of claim 17, wherein Compound 1, or a pharmaceutically acceptable salt, or solvate thereof, is administered in amount equivalent to about 5 mg to about 300 mg of Compound 1.

### Claim 38 (depends on 37)

The method of claim 37, wherein Compound 1, or a pharmaceutically acceptable salt, or solvate thereof, is administered in amount equivalent to about 10 mg to about 250 mg of Compound 1.

### Claim 39 (depends on 17)

The method of claim 17, wherein Compound 1, or a pharmaceutically acceptable salt, or solvate thereof, is administered in amount equivalent to about: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 185 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, 240 mg, 245 mg, 250 mg, 255 mg, 260 mg, 265 mg, 270 mg, 275 mg, 280 mg, 285 mg, 290 mg, 295 mg, or 300 mg of Compound 1.

### Claim at position 25

-60. (canceled)
